Vesalius Biocapital Partners
Europe, Luxembourg, Luxembourg, Strassen
Description
Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007.
Investor Profile
Vesalius Biocapital Partners has made 54 investments, with 6 in the past 12 months and 41% as lead.
Stage Focus
- Series B (30%)
- Series A (30%)
- Series C (20%)
- Series Unknown (9%)
- Seed (4%)
- Post Ipo Equity (2%)
- Series D (2%)
- Private Equity (2%)
- Series E (2%)
Country Focus
- Germany (26%)
- Belgium (24%)
- United States (13%)
- Switzerland (9%)
- The Netherlands (9%)
- France (6%)
- United Kingdom (4%)
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
- Portugal (4%)
'/%3e%3c/g%3e%3cuse xlink:href='%23d' x='45.714'/%3e%3cuse xlink:href='%23e' transform='matrix(-1 0 0 1 479.792 0)'/%3e%3cg id='f' fill='%23fff'%3e%3cpath fill='%23039' d='M232.636 202.406v.005c0 2.212.85 4.227 2.212 5.69 1.365 1.466 3.245 2.377 5.302 2.377 2.067 0 3.944-.905 5.303-2.365 1.358-1.459 2.202-3.472 2.202-5.693v-10.768l-14.992-.013-.028 10.766'/%3e%3ccircle cx='236.074' cy='195.735' r='1.486'/%3e%3ccircle cx='244.392' cy='195.742' r='1.486'/%3e%3ccircle cx='240.225' cy='199.735' r='1.486'/%3e%3ccircle cx='236.074' cy='203.916' r='1.486'/%3e%3ccircle cx='244.383' cy='203.905' r='1.486'/%3e%3c/g%3e%3cuse xlink:href='%23f' y='-26.016'/%3e%3cuse xlink:href='%23f' x='-20.799'/%3e%3cuse xlink:href='%23f' x='20.745'/%3e%3cuse xlink:href='%23f' y='25.784'/%3e%3c/svg%3e)
- Finland (4%)
- Canada (2%)
Industry Focus
- Health Care
- Biotechnology
- Medical
- Therapeutics
- Pharmaceutical
- Health Diagnostics
- Medical Device
- Software
- Artificial Intelligence (Ai)
- Analytics
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
